These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 28625400)

  • 1. Successful treatment of ventricular fibrillation storm triggered by short-long-short sequence; time to avoid managed ventricular pacing.
    Alnsasra H; Konstantino Y; Bereza S; Haim M
    J Electrocardiol; 2017; 50(6):941-943. PubMed ID: 28625400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managed ventricular pacing compared with conventional dual-chamber pacing for elective replacement in chronically paced patients: results of the Prefer for Elective Replacement Managed Ventricular Pacing randomized study.
    Botto GL; Ricci RP; Bénézet JM; Nielsen JC; De Roy L; Piot O; Quesada A; Quaglione R; Vaccari D; Garutti C; Vainer L; Kozák M;
    Heart Rhythm; 2014 Jun; 11(6):992-1000. PubMed ID: 24418164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
    JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QRS Fragmentation and QTc Duration Relate to Malignant Ventricular Tachyarrhythmias and Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.
    Debonnaire P; Katsanos S; Joyce E; VAN DEN Brink OV; Atsma DE; Schalij MJ; Bax JJ; Delgado V; Marsan NA
    J Cardiovasc Electrophysiol; 2015 May; 26(5):547-55. PubMed ID: 25648421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bradycardia pacing-induced short-long-short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia?
    Sweeney MO; Ruetz LL; Belk P; Mullen TJ; Johnson JW; Sheldon T
    J Am Coll Cardiol; 2007 Aug; 50(7):614-22. PubMed ID: 17692746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switch between AAI and DDD mode pacing-What is the mechanism?
    Ząbek A; Małecka B; Nowosielska-Ząbek E; Dębski M; Boczar K; Lelakowski J
    Ann Noninvasive Electrocardiol; 2019 Jul; 24(4):e12648. PubMed ID: 30896054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy.
    O'Mahony C; Lambiase PD; Rahman SM; Cardona M; Calcagnino M; Quarta G; Tsovolas K; Al-Shaikh S; McKenna W; Elliott P
    Europace; 2012 May; 14(5):724-33. PubMed ID: 22094454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Implantation of a dual chamber pacemaker-defibrillator (DDD-ICD) in a patient with hypertrophic obstructive cardiomyopathy].
    Neuberger HR; Mewis C; Dörnberger V; Bosch RF; Kühlkamp V
    Z Kardiol; 1999 Jul; 88(7):521-5. PubMed ID: 10467652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized pilot study of a new atrial-based minimal ventricular pacing mode in dual-chamber implantable cardioverter-defibrillators.
    Sweeney MO; Shea JB; Fox V; Adler S; Nelson L; Mullen TJ; Belk P; Casavant D; Sheldon T
    Heart Rhythm; 2004 Jul; 1(2):160-7. PubMed ID: 15851147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventricular fibrillation induced by rapid atrial rates in patients with hypertrophic cardiomyopathy.
    López Gil M; Arribas F; Cosío FG
    Europace; 2000 Oct; 2(4):327-32. PubMed ID: 11194600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.
    Maurizi N; Tanini I; Olivotto I; Amendola E; Limongelli G; Losi MA; Allocca G; Perego GB; Pieragnoli P; Ricciardi G; De Filippo P; Ferrari P; Quarta G; Viani S; Rapacciuolo A; Bongiorni MG; Cecchi F
    Int J Cardiol; 2017 Mar; 231():115-119. PubMed ID: 28073660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
    Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter, prospective, randomized safety and efficacy study of a new atrial-based managed ventricular pacing mode (MVP) in dual chamber ICDs.
    Sweeney MO; Ellenbogen KA; Casavant D; Betzold R; Sheldon T; Tang F; Mueller M; Lingle J;
    J Cardiovasc Electrophysiol; 2005 Aug; 16(8):811-7. PubMed ID: 16101620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA; Link MS; Semsarian C; Shen WK; Estes NA; Maron MS; Haas TS; Formisano F; Boriani G; Spirito P; Maron BJ
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.